Meningococcal PPT OUTLINE ATTACHED

I. Definition

II. Cause of the disease

Need to know

a. Overview: Some people are at a high risk of contracting meningococcal disease. The risks involve travel, age, community setting, and certain medical conditions (Ghebrehewet, Conrad & Marsh, (2016).

b. Meningococcal vaccination: several vaccines are available to children and adults

I. Transmission: The disease is causes by Neisseria Meningitides. It is classified as airborne disease because it is transmitted through kissing or coughing.

· Signs & symptoms: The disease present the signs and symptoms of flu-illness, and can have additional signs such as fever, headache, nausea, vomiting, altered mental status, among others (Tsang & Taha, 2016)

· Prevention: Vaccines and antibiotics appear to be the most effective (Pollard, Feavers & Cohn, 2016).

· Meningococcal conjugate vaccine (MCV4) 

9 months to 55 years Menactra

2 years old to 55 years old Menveo

· Meningococcal polysaccharide vaccine (MPSV4)

· Serogroup B Meningococcal B 

 

I. Treatment: Treatment is mainly based on the use of antibiotics (Nadel & Carcillo, 2016)

II. Conclusion

References

Brandtzaeg, P. (2006). Pathogenesis and Pathophysiology of Invasive Meningococcal Disease. Handbook of Meningococcal Disease, 427-480. doi:10.1002/3527608508.ch21

Ghebrehewet, S., Conrad, D., & Marsh, G. (2016). Meningitis and meningococcal disease. Oxford Medicine Online. doi:10.1093/med/9780198745471.003.0011

Nadel, S., & Carcillo, J. (2016). Treatment of meningococcal disease. Handbook of Meningococcal Disease Management, 75-90. doi:10.1007/978-3-319-28119-3_6

Pollard, A. J., Feavers, I., & Cohn, A. (2016). Prevention of meningococcal disease through vaccination. Handbook of Meningococcal Disease Management, 91-103. doi:10.1007/978-3-319-28119-3_7

Tsang, R., & Taha, M. (2016). Diagnosis of meningococcal disease. Handbook of Meningococcal Disease Management, 45-55. doi:10.1007/978-3-319-28119-3_4